Acute Coronary Syndrome

A little less than half of atherosclerotic cardiovascular disease (ASCVD) patients are treated for blood cholesterol according to 2013 clinical guidelines, with around half missing out on a statin prescription the guidelines would have recommended, according to a study published in the American Journal of Cardiology.

Stress disorders like PTSD and adjustment disorder were linked to adverse cardiovascular outcomes in a recent BMJ study, Reuters reports, with the greatest CV risk posed in the months directly after a patient is diagnosed with such a condition.

MicroRNAs could be key to treating heart failure, according to a study out of Boston Children’s Hospital and Zhejiang University School of Medicine in China.

Antibiotic use—particularly regimens that last for two months or more—was linked to an increased risk of CVD in a recent study of nearly 36,500 older women.

A study of nearly 4,000 patients with coronary artery disease (CAD) has linked blood pressure variability (BPV) between clinic visits to significantly greater progression of coronary atheroma and major adverse events, suggesting BP stability might be an important factor in CAD care.

Eating a late dinner and skipping breakfast could raise heart patients’ risk of a repeat MI or death by up to fivefold, according to research published in the European Journal of Preventive Cardiology April 17.

The 71-year-old Framingham Heart Study has received $38 million from the National Heart, Lung, and Blood Institute to fund a new six-year study into the biology of aging.

More than 80% of stable patients with ST-segment elevation myocardial infarction (STEMI) are treated in the intensive care unit despite only 16% of them experiencing complications that require an ICU stay, according to a U.S. registry analysis published in JACC: Cardiovascular Interventions.

When couples attended smoking cessation programs together, their odds of quitting were nearly six times higher than for people who attempted to kick the habit alone, according to preliminary research presented April 12 at EuroPrevent 2019.

A team-based protocol for treating cardiogenic shock helped one center boost its 30-day survival rates for those patients by nearly 20 percentage points over a two-year period, researchers reported in the Journal of the American College of Cardiology.

The FDA has granted a breakthrough therapy designation to a novel reversal agent for ticagrelor called PB2452, PhaseBio Pharmaceuticals announced April 8.

Nursing home residents who were prescribed three or four preventive medications after myocardial infarction (MI) were 26% less likely to die within 90 days than those prescribed only one drug, researchers reported April 9 in Circulation: Cardiovascular Quality and Outcomes.